Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review examines the placebo response in conditions such as allergies and weight loss, highlighting its significance in both conventional and alternative medicine randomized trials, without reporting any new results.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

In this study, finasteride was found to reduce costs associated with benign prostatic hyperplasia compared to watchful waiting and terazosin, especially in men with higher prostate-specific antigen levels.

This review discusses the pathophysiology of delayed ejaculation, highlighting the role of various biogenic and psychogenic factors, but reports no new clinical findings.

This article reviews the effects of 5 alpha-reductase inhibitors for treating conditions like male pattern baldness and benign prostatic hyperplasia, noting significant DHT reduction but reports no new clinical results.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

In this study, corn silk extract treatment improved symptoms of testosterone-induced BPH by reducing specific mRNA expression and decreasing levels of 5α-R2, DHT, and PSA.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This paper reviews the role of pharmacokinetic/pharmacodynamic modeling in drug development, emphasizing its application for drug dosing guidance, safety resolution, and therapeutic monitoring improvement, without presenting new clinical results.

This study constructed a model to predict finasteride's inhibitory activity on 5α-reductase type 2 and calculated that a 1 μM plasma concentration, after 50 mg administration, matches prostate inhibition levels.

This review discusses the potential benefits of pumpkin seed oil for men's health, particularly in conditions such as benign prostatic hyperplasia, overactive bladder, and androgenic alopecia, but reports no new clinical results.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This review discusses sexual dysfunction as a side effect of α-blockers and 5-ARIs for BPH/LUTS, highlighting methodological flaws in existing studies and the need for more rigorous research.

This article summarizes the MHRA report on finasteride and does not present new clinical findings.

Dutasteride reduces DHT more effectively than finasteride.

Researchers observed that dutasteride and finasteride caused structural changes in the penises of both control and hypertensive rats, with dutasteride having a more pronounced effect on the corpus cavernosum.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

Combination therapy for BPH is cost-effective, especially for men with larger prostates.

In this study, co-administration of finasteride with oral testosterone undecanoate in young men with induced hypogonadism had no significant effect on serum testosterone or dihydrotestosterone levels, likely due to TU's unique absorption route.

This study validated a highly selective and fast LC–MS/MS method for accurately measuring levels of tadalafil and finasteride in human plasma, adhering to international bioanalytical guidelines.

This study in rats suggests that combining the 5 alpha-reductase inhibitor 4-MA with the antiandrogen Flutamide may enhance prostate cancer therapy by additively inhibiting prostatic growth and mRNA levels of androgen-sensitive prostatic binding proteins.

This review discusses post-finasteride syndrome, emphasizing its serious psychological and cognitive symptoms and the need for more research and awareness in the medical community, but provides no new clinical findings.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

This study found that KH053, combining Panax ginseng and bee-pollen, significantly reduced prostate weight and DHT levels, inhibiting BPH development in a rat model.

This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.

This study found that patients with androgenetic alopecia had a higher incidence of metabolic syndrome and benign prostatic hyperplasia compared to those without the condition.

Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.